Mar 25, 2025 (PRISM News via COMTEX) --
Predictive Oncology Soars 72% on Major Drug Discovery Milestone
Predictive Oncology Inc. (POAI) surged over 70% to lead the PRISM NextGen Tech & AI Index after announcing the successful development of predictive models from 21 never-before-seen natural compounds. Using its AI-driven platform and partnering with the University of Michigan's Natural Products Discovery Core, the company identified several compounds that showed strong anti-tumor activity across breast, colon, and ovarian cancers--some outperforming benchmark chemotherapy agent Doxorubicin. The development signals a meaningful step forward in AI-enabled drug discovery and early-stage oncology research.
CorMedix Tumbles 34% Despite Reporting First Profitable Quarter
Shares of CorMedix Inc. (CRMD) plunged over 30%, dragging the PRISM Emerging Pharmaceuticals Index lower, following the company's Q4 and full-year 2024 financial results. While CorMedix posted its first profitable quarter with $31.2M in revenue and $13.5M in net income, investor sentiment turned negative on full-year losses, rising operational expenses, and cautious guidance. The launch of DefenCath drove the quarterly gains, but concerns remain over future growth pacing and cash burn despite strong initial commercialization metrics.
In other news, Moleculin Biotech, Inc. (MBRX), another PRISM Emerging Pharmaceuticals Index company, rose 23% after reporting FY 2024 financial results and providing a corporate update. The company confirmed it is on track to treat the first patient in its pivotal Phase 3 MIRACLE trial for relapsed/refractory acute myeloid leukemia in Q1 2025, with initial data expected in the second half of the year. Positive regulatory guidance, site activations in multiple countries, and early enrollment progress appear to be supporting investor sentimentâ??.
Other PRISM Mid-Day Movers: SES AI Corporation (SES) up 17%, IO Biotech, Inc. (IOBT) up 23%, and Plus Therapeutics, Inc. (PSTV) up 22%.
The post PRISM Mid-Day Movers: AI Breakthroughs and Biopharma Volatility appeared first on PRISM MarketView.
COMTEX_463931088/2927/2025-03-25T15:00:18
